Botox needle size study among recent cosmetic dermatology developments

Recent cosmetic developments reported on Healio.com/Dermatology included study results reporting greater incidence of clinically significant pain with Botox facial injections using 30-gauge needles compared with 32-gauge needles.

Other developments included the introduction of a new blog by dermatologist Kimberly J. Butterwick, MD, and the FDA warning consumers that it has not approved any injectable drugs for skin whitening or lightening:

Needle size determined clinically significant pain in Botox facial injections

There was a greater incidence of clinically significant pain with Botox facial injections using 30-gauge needles compared with 32-gauge needles, according to recently published study results.

Twenty women with moderate dynamic forehead and glabellar wrinkles were treated with Botox (onabotulinum toxin A, Allergan) in saline injected with a 32-gauge needle on one side of the forehead, while the other side received the same treatment injection with a 30-gauge needed. Read more

BLOG: Global advances in minimally invasive aesthetics

In her new blog, Kimberly J. Butterwick, MD, reports on her participation in a session called, “The State of the Art in Minimally Invasive Aesthetics,” sponsored by the American Society of Dermatologic Surgery, held the day before the start of the World Congress of Dermatology in Vancouver, British Columbia.

Kimberly J. Butterwick

“Given that the FDA had just issued a warning about vascular adverse events related to fillers, the sessions on fillers were particularly timely and informative,” Butterwick reports.

FDA warns consumers about injectable skin lightening products

The FDA warned consumers that it has not approved any injectable drugs for skin whitening or lightening, according to a recent consumer alert.

“These products pose a potentially significant safety risk to consumer. You’re essentially injecting an unknown substance into your body—you don’t know what it contains or how it was made,” In Kim, FDA pharmacist, said in the alert. Read more

Suneva announces five-year study results confirming safety, effectiveness of Bellafill

Suneva Medical announced that Bellafill demonstrated safety and effectiveness in a five-year post-approval study for nasolabial folds.

The study of Bellafill was the largest and longest prospective dermal filler study ever conducted, and included high patient satisfaction, according to a press release. Read more

SculpSure receives CE Mark approval

Cynosure announced in a press release that it has received European Medical Device Directive certification for its SculpSure hyperthermic aesthetic laser treatment for noninvasive fat reduction.

The certification from Cynosure’s European Notified Body, Intertek Semko AB, will allow Cynosure to place the CE Mark on SculpSure to distribute throughout member states of the European Union, according to the release. Read more